METiS Pharmaceuticals-preview

Metis-pharmaceuticals

METiS Pharmaceuticals

Private

Hangzhou, ZhejiangHealthcare & Life Scienceshttps://www.metispharmaceuticals.cn

Last Round

Series D

8/4/2025

Total Funding Raised

$391.6M

Company Overview

Metis Pharmaceuticals is a biotechnology company that offers an artificial intelligence platform to enhance pharmaceutical formulation processes and streamline pre-clinical trial operations for faster drug development.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting, Revenue Share

AI Layer

Application

Keywords

AI drug discoverydrug formulationdrug deliveryTechBioLipid Nanoparticle deliveryLNP deliveryAIDDnucleic acid therapeuticsAI biotechsmall molecule drugsdrug discovery platformmRNA therapeuticspreclinical developmenthigh-throughput experimentationlab automationcell and gene therapyCGTquantum simulation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

METiS Pharmaceuticals Comps

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

METiS Pharmaceuticals Funding Rounds

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Series D	8/4/2025
Series C	6/22/2024
Series B	4/5/2022
Series A	12/7/2021
Angel	12/3/2020
Angel	3/23/2020

View all Funding Rounds

METiS Pharmaceuticals Investors

Notable investors and investment history

Investor	Rounds
Taiping Hong Kong Insurance Innovation and Technology Venture Fund	Series C
招银国际金融有限公司	Series B
China International Capital Corporation	Series C
Monolith Management	Series C, Series B
PICC Capital Insurance Asset Management	Series B
Lightspeed China Partners	Angel, Series A, Series B
5Y Capital	Series A, Series B

View all Investors

METiS Pharmaceuticals Filings

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

METiS Pharmaceuticals Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about METiS Pharmaceuticals's valuation, stock price, and market status.

Firmographic Details

HeadquartersHangzhou, Zhejiang

Employee Range5

Year Founded2019

Last Funding8/4/2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

Login

Use CasesInvestors Employees

CompaniesAll Companies

LegalPrivacy Policy Terms of Use BrokerCheck Form CRS

DisclaimerAll investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.